Recce Pharmaceuticals Ltd.ASX: RCE

Appendix 4D and Interim Financial Report

· Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · · 25 pages · English

Summary by 6ix AI

The report highlights a substantial increase in the loss from ordinary activities after tax compared to the previous year, attributed mainly to increased research and development costs. The company did not declare any dividends during this period, maintaining a focus on funding its ongoing operations through various means.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

Later from Recce Pharmaceuticals

All Recce Pharmaceuticals news releases